	US 11,945,803 B2
	Modulators of RAS GTPase
Annie L. Lennek, Mountain View, CA (US); Stephen D. Yanofsky, Mountain View, CA (US); Brian D. Frenzel, Mountain View, CA (US); Solomon B. Ungashe, Mountain View, CA (US); William A. Garland, Mountain View, CA (US); and Philip Liaw, Mountain View, CA (US)
Assigned to Tosk, Inc., Mountain View, CA (US)
Appl. No. 17/260,711
Filed by Tosk, Inc., Mountain View, CA (US)
PCT Filed Aug. 6, 2019, PCT No. PCT/US2019/045315 § 371(c)(1), (2) Date Jan. 15, 2021, PCT Pub. No. WO2020/033413, PCT Pub. Date Feb. 13, 2020.
Claims priority of provisional application 62/715,505, filed on Aug. 7, 2018.
Prior Publication US 2021/0261532 A1, Aug. 26, 2021
Int. Cl. C07D 403/14 (2006.01); C07D 413/12 (2006.01)

CPC C07D 403/14 (2013.01) [C07D 413/12 (2013.01)]

9 Claims

1. A pharmaceutical composition comprising a therapeutically effective amount of a RAS modulating compound of the formula:

Cy₁-Cy₂—(CR¹R²)_n—Y¹—(CR¹R²)_m-Cy₃

wherein:

Cy1 is a cyclic group selected from an oxadiazole and a thiadiazole;

Cy2 is a phenyl:

Cy3 is a pyrazole, wherein Cy1, Cy2 and Cy3 are optionally further substituted;

n and m are each independently 0, 1, 2, 3, 4, 5 or 6, wherein n+m is less than 7; each R1 and each R2 is independently H, an alkyl or a substituted alkyl; and

Y1 is selected from —CONR—, —NRCO—, —NRSO2- and —SO2NR— wherein R is H, an alkyl or a substituted alkyl;

or a salt thereof, and a pharmaceutically acceptable vehicle.